Skip to content
Open access

Preoperative Weight Loss Before Total Joint Arthroplasty Using Novel Glucagon-Like Peptide-1 Agonists

Aug 2026 · Arthroplasty Today · Vol 41 · 0 citations · 27 references
Medicine

Abstract

Background This study determined the prevalence of glucagon-like peptide-1 (GLP-1) use before total joint arthroplasty (TJA), measured weight loss of patients on GLP-1s, and evaluated if GLP-1s were associated with outcomes. Methods We identified 6482 patients (2990 hips; 3492 knees) who had primary TJAs between 2019 and February 2023. The mean age was 67 years, 50% were female, and 12% had a body mass index ≥40 kg/m2. Univariable and multivariable models evaluated outcomes. Mean follow-up was 3 years. Results The prevalence of GLP-1s before TJA was 3%, increasing from 2% in 2019 to 5% in 2022. The mean preoperative weight change on GLP-1s was −9 pounds (range, −110 to +36 pounds). Among patients taking GLP-1s, 19% lost ≥20 pounds prior to surgery, and the mean body mass index change was −1.4 kg/m2 (range, −16.3 to 6.2 kg/m2). In univariable analyses, GLP-1 use was not associated with revisions (P = .35), reoperations (P = .09), or complications (P = .23). In multivariable analyses, GLP-1s were not associated with revisions (P = .66), reoperations (P = .34), or complications (P = .85). There was no difference in the risk of a 90-day postoperative emergency department visit between those on GLP-1s vs not on those medications (odds ratio, 1.5; P = .07). Conclusions The prevalence of preoperative GLP-1s before TJA increased from 2% in 2019 to 5% in 2022, and preoperative weight change on GLP-1s varied considerably. GLP-1s were not associated with decreased postoperative risks but investigational GLP-1s before TJA require further study. Level of Evidence Level III.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.